Sugi Predict

Sugi Predict / Compounds / SCHEMBL1430701

SCHEMBL1430701

SCHEMBL1430701

CC(=O)Nc1ccc(C)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ KCNQ3 O43525 1/20 0.54
▸ KCNQ2 O43526 1/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ HTT P42858 1/20 0.52
▸ MEN1 O00255 6/20 0.50
▸ KMT2A Q03164 6/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ SORT1 Q99523 1/20 0.50
▸ CA12 O43570 1/20 0.50
▸ BRD4 O60885 1/20 0.50
▸ NR1I2 O75469 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ MB P02144 1/20 0.50
▸ CYP1A1 P04798 1/20 0.50
▸ CA3 P07451 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30421055 1.00 NPSR1 (0.55) NPSR1TDP1KCNQ3KCNQ2SMN1; SMN2
SCHEMBL2242286 0.86 NPSR1 (0.57) NPSR1KCNQ3KCNQ2SMN1; SMN2MEN1
SCHEMBL30919458 0.86 NPSR1 (0.57) NPSR1KCNQ3KCNQ2SMN1; SMN2MEN1
SCHEMBL2666327 0.85 NPSR1 (0.53) NPSR1KCNQ3KCNQ2SMN1; SMN2HTT
Hydrochloric Acid SCHEMBL23213944 0.84 NPSR1 (0.55) NPSR1KCNQ3KCNQ2SMN1; SMN2MEN1
SCHEMBL4007229 0.82 NPSR1 (0.54) NPSR1KCNQ3KCNQ2SMN1; SMN2ALDH1A1
SCHEMBL19776335 0.82 NPSR1 (0.58) NPSR1KCNQ3KCNQ2SMN1; SMN2HTT
SCHEMBL7964257 0.82 SMN1; SMN2 (0.54) TDP1SMN1; SMN2L3MBTL1HTTMEN1
SCHEMBL12049698 0.81 NPSR1 (0.60) NPSR1KCNQ3KCNQ2SMN1; SMN2MEN1
SCHEMBL31129251 0.81 NPSR1 (0.56) NPSR1KCNQ3KCNQ2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217933-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2024-07-04 — — US disclosed
WO-2024094819-A1 NEK7 DEGRADERS AND METHODS OF USE THEREOF CAPTOR THERAPEUTICS S.A. (PL) 2024-05-10 — — WO disclosed
WO-2024096753-A1 NEK7 DEGRADERS AND METHODS OF USE THEREOF CAPTOR THERAPEUTICS S.A. (PL) 2024-05-10 — — WO disclosed
US-20230373955-A1 SYNTHESIS OF OMECAMTIV MECARBIL AMGEN INC. 2023-11-23 — — US disclosed
WO-2023215367-A1 BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF CYTOKINETICS, INC. (US) 2023-11-09 — — WO disclosed
US-11753394-B2 Synthesis of omecamtiv mecarbil AMGEN INC. (US) 2023-09-12 — — US disclosed
US-11702380-B2 Synthesis of omecamtiv mecarbil AMGEN INC. (US) 2023-07-18 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2023081845-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2022236253-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC. (US) 2022-11-10 — — WO disclosed
WO-2010130034-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-18 — — WO disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 — — US disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 — — US disclosed
EP-2189449-A1 AMINOPYRAZOLE AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2010-05-26 — — EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 — — WO disclosed
WO-2009138707-A1 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2009-11-19 — — WO disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 — — US disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 — — US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 — — US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275085-A1 Piperidine derivative and use thereof TACR2, TACR1, PRLHR NPSR1 17/4885TDP1 4456/4885KCNQ3 268/4885
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 NPSR1 3647/4885TDP1 966/4885KCNQ3 3954/4885
US-11702380-B2 Synthesis of omecamtiv mecarbil SI, MTHFD2, DPYD NPSR1 3825/4885TDP1 3903/4885KCNQ3 4852/4885
US-20230373955-A1 SYNTHESIS OF OMECAMTIV MECARBIL DPYD, SI, MTHFD2 NPSR1 3972/4885TDP1 3895/4885KCNQ3 4811/4885
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS MET, DMPK, RET NPSR1 2995/4885TDP1 2437/4885KCNQ3 3765/4885
US-11753394-B2 Synthesis of omecamtiv mecarbil SI, DPYD, MTHFD2 NPSR1 4010/4885TDP1 4087/4885KCNQ3 4785/4885
US-20240217933-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES SI, MLN, MLNR NPSR1 2667/4885TDP1 4010/4885KCNQ3 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.